Swine Foot and Mouth Disease (Type O) Vaccine, Inactivated (Strain OZK/93) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a purified inactivated viral antigen preparation derived from the OZK/93 isolate of foot-and-mouth disease virus serotype O. The strain designation identifies the isolate from which the master seed is prepared; it is not a trade name or a potency class. The active fraction is the intact 146S whole-virus capsid, not total viral protein or total dry matter. The product is supplied as a bulk active pharmaceutical ingredient under veterinary good manufacturing practice principles, and the listed presentations—tablets, injections, capsules, powders, granules, premix, and solutions—describe possible physical forms or downstream formulation intermediates. They do not by themselves establish that every route or dosage form is immunologically appropriate. The recognized protective route for inactivated foot-and-mouth disease antigen in swine remains parenteral administration of adjuvanted vaccine. Any oral solid-dosage claim would require independent evidence that the 146S particle survives gastrointestinal transit and reaches an immunologically relevant site.

The term “Veterinary Grade API” is not identical to a finished vaccine. For this inactivated viral antigen, potency cannot be expressed solely as a mass-per-tablet or mass-per-millilitre value. Potency is determined by intact 146S content, the antigenic match between OZK/93 and the field isolate, and the adjuvant system used in the final formulation. The same bulk antigen may be formulated into an injectable aqueous suspension, a water-in-oil emulsion, or a lyophilised intermediate, but the release specification must be revalidated for each presentation. The product is intended exclusively for veterinary use in swine and is not for human administration.

What is the functional identity of the 146S antigen in downstream formulation?

Foot-and-mouth disease virus serotype O contains a single-stranded positive-sense RNA genome enclosed in an icosahedral capsid assembled from the structural proteins VP1, VP2, VP3, and VP4. The intact virion has a sedimentation coefficient of approximately 146S; this is the immunogenically relevant particle. Acidic conditions below pH 6.8 dissociate the capsid into pentameric 12S subunits and reduce protective immunogenicity. Downstream formulation of the OZK/93 API therefore requires buffering in the neutral range, typically pH 7.2–7.8 for aqueous finished products, with the exact limits controlled by the manufacturer. Exposure to pH values below 6.0 during inactivation, clarification, or purification can cause irreversible loss of conformational epitopes, even if total protein concentration remains unchanged. Consequently, the analytical distinction between total protein and intact 146S antigen is a primary release concern. A preparation with high total protein and low 146S content represents a degraded or poorly preserved antigen.

Clarified virus harvest is concentrated by ultrafiltration or tangential-flow filtration. The membrane molecular weight cut-off must retain the viral particle while allowing host-cell proteins and low-molecular-weight medium components to pass. Because foot-and-mouth disease virus is non-enveloped, solvent-detergent inactivation steps used for enveloped viruses are not applicable. Inactivation is achieved chemically, most commonly with binary ethylenimine, which alkylates viral nucleic acid while preserving capsid structure. The resulting antigen cannot replicate. This is a critical difference from live attenuated vaccine platforms: the inactivated OZK/93 product presents the whole capsid but does not generate productive infection.

When the inactivated antigen is processed into dry oral forms, formulation constraints shift

Although the listed presentations include tablets, capsules, powders, granules, and premix, processing this inactivated viral antigen into a dry oral dosage form is not equivalent to tableting a thermostable small-molecule active. The OZK/93 antigen is acid-labile and thermally sensitive. Swine gastric pH can fall below 2.0, which is incompatible with intact viral antigen. A tablet or capsule formulation would therefore require an enteric-coating or microencapsulation barrier to prevent antigen degradation before the particle reaches neutral intestinal segments. The finished oral form would also require a dissolution or release test that demonstrates antigen integrity by a validated enzyme-linked immunosorbent assay or particle-specific method. Direct compression without protective excipients is contraindicated for this biological active. Published data for the specific behaviour of OZK/93 in solid oral matrices is limited, so feasibility cannot be assumed without laboratory-scale stability screening under simulated gastrointestinal conditions.

Granules and premixes intended for feed or drinking-water administration face the same barrier and stability constraints. If the product is supplied as a granulated intermediate for extemporaneous reconstitution into an injectable or oral solution, the granulation binder must be selected for low shear and low residual moisture. Agglomeration processes that generate localized heat above 25 °C should be supported by stability data. In the absence of published OZK/93 tablet-compression data, any tableting process should be screened by measuring antigen integrity before and after compression. A formulation acceptable for a small-molecule API is not automatically suitable for this inactivated viral antigen.

Release testing must address sterility, endotoxin, residual inactivant, and 146S integrity

A release panel for inactivated foot-and-mouth disease antigen is not limited to the chemical assays used for small-molecule active ingredients. The viral seed lot system, working seed, and production harvest are controlled according to the principles in the WOAH Terrestrial Manual Chapter 3.1.8 and, where applicable, the European Pharmacopoeia monograph 0063. Sterility is evaluated by membrane filtration or direct inoculation using soybean-casein digest and fluid thioglycollate media; compendial methods include Ph. Eur. 2.6.1 and USP 71. Bacterial endotoxin testing is conducted by limulus amoebocyte lysate methods per Ph. Eur. 2.6.14 or USP 85. Inactivation is validated by demonstrating absence of residual infectivity after binary ethylenimine treatment, typically through at least two blind passages in susceptible cell culture with observation for cytopathic effect. The final bulk may also be tested for residual inactivant or its degradation products using a validated chromatographic or titrimetric method. Numerical acceptance limits for total protein, 146S content, pH, endotoxin, and residual moisture are assigned by the marketing authorization holder and are presentation-specific.

The parenteral route remains the recognized route for protective vaccination. Aluminium hydroxide and saponin adjuvants are typical for aqueous foot-and-mouth disease vaccines, whereas oil-in-water and water-in-oil adjuvants are used to prolong antigen release. Adjuvant compatibility with OZK/93 must be confirmed by emulsion stability testing, droplet size distribution, and in vivo potency. An adjuvant concentration used for a different foot-and-mouth disease strain cannot be assumed to produce identical results with OZK/93. Finished injectable vaccine is administered intramuscularly in the neck region of swine according to the marketing authorization; dose volume and revaccination interval are not fixed by the API supplier.

Storage of the inactivated OZK/93 antigen follows biological product principles. Liquid bulk is typically maintained at 2–8 °C and must not be frozen unless the presentation is a validated lyophilised preparation. Freeze-thaw cycles without cryoprotectant can destroy the 146S particle, and the resulting preparation may pass a protein assay while failing potency. Lyophilised powders should be sealed under dry conditions and reconstituted immediately before use. The product should not be mixed with amine-based disinfectants or strong oxidising agents, and contact with acidic cleaning solutions must be avoided because of the same pH lability that governs formulation stability. In the manufacturing environment, residual hypochlorite or quaternary ammonium compounds must be rinsed thoroughly because chemical incompatibility can reduce antigen recovery.

Comparative strain and platform boundaries

The OZK/93 strain is a Type O foot-and-mouth disease virus isolate. It is not synonymous with other Type O vaccine strains such as O1 Manisa, O 3039, or O Taiwan. Strain differences arise from nucleotide and amino acid substitutions in the VP1 structural protein and from changes in capsid surface epitopes. A vaccine prepared from OZK/93 may not protect against every Type O field isolate. WOAH antigenic matching guidance uses the r1 value from virus neutralisation tests; an r1 value of at least 0.3 is generally interpreted as indicating an acceptable antigenic match. An r1 value below 0.3 indicates a poor match and should prompt selection of another strain. Published data for the specific cross-protection profile of OZK/93 is limited, so a field-isolate matching exercise is required before inclusion in an emergency or routine vaccination program.

Compared with other vaccine platforms, the inactivated whole-virus antigen maintains the complete capsid structure after inactivation and presents conformational neutralising epitopes in a quaternary context. Live attenuated foot-and-mouth disease vaccines are not used in most national control programs because of reversion and transmission risk; the inactivated OZK/93 preparation eliminates replication but requires higher antigen payload and an adjuvant. Synthetic peptide and virus-like particle vaccines may target specific VP1 G-H loop sequences, but they may present fewer conformational epitopes than the whole viral capsid.

Seed lot propagation, inactivation kinetics, and concentration do not follow small-molecule synthesis routes. The production process commonly relies on BHK-21 suspension cell culture, although other validated cell substrates may be used. Virus multiplication is followed by clarification, concentration, inactivation with binary ethylenimine, and purification to remove host-cell material. The master seed and working seed are tested for identity, sterility, mycoplasma, extraneous viruses, and relevant biological properties. Material traceability is maintained from seed lot to final dosage form. The final antigen bulk is released only after inactivation confirmation and potency testing. Because foot-and-mouth disease virus is a high-consequence pathogen, production must be conducted in an approved biosecure facility, and local regulatory requirements for inactivated antigen handling must be observed.

The listed dosage forms should therefore be interpreted as presentation codes for a biological active rather than as interchangeable pharmaceutical formats. An injectable solution or emulsion is the standard presentation for this inactivated OZK/93 antigen. Tablets, capsules, powders, granules, and premixes are not established commercial foot-and-mouth disease vaccine formats and require formulation-specific protection, stability, and efficacy data before use. The product is a prophylactic antigen, not an antiviral drug, and is not indicated for treatment of infected animals.